{
  "resourceType": "PlanDefinition",
  "id": "plandefinition-cervical-cancer",
  "meta":{
    "profile": [
      "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-plandefinition"
    ]
  },
  "text": {
    "status": "generated",
    "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The USPSTF recommends screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years.</p>\r\n<p>For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with hrHPV testing in combination with cytology (cotesting).</p>\r\n<p>&nbsp;</p>\r\n<p>See the&nbsp;<a href=\"https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/cervical-cancer-screening2#consider\">Clinical Considerations section</a><span>&nbsp;for the relative benefits and harms of alternative screening strategies for women 21 years or older</span></p>\r\n<p>&nbsp;</p></div>"    
  },
  "extension": [
    {
      "url": "http://example.com/cedar-risk-factor",
      "valueString": "<p><span>All women aged 21 to 65 years are at risk for cervical cancer because of potential exposure to high-risk HPV types (hrHPV) through sexual intercourse and should be screened. Certain risk factors further increase risk for cervical cancer, including HIV infection, a compromised immune system, in utero exposure to diethylstilbestrol, and previous treatment of a high-grade precancerous lesion or cervical cancer. Women with these risk factors should receive individualized follow-up.</span></p>"
    }
  ],
  "url": "http://example.com/fhir/PlanDefinition/plandefinition-cervical-cancer",
  "version": "2020.1",
  "name": "Plandefinition_cervical_cancer",
  "title": "Cervical Cancer: Screening --Women aged 21 to 65 years",
  "type": {
    "coding": [
      {
        "system": "http://terminology.hl7.org/CodeSystem/plan-definition-type",
        "code": "eca-rule",
        "display": "ECA Rule"
      }
    ]
  },
  "status": "active",
  "experimental": false,
  "subjectReference": {
    "reference": "Group/group-female-21-65",
    "display": "Female aged between 21 and 65"
  },
  "date": "2020-12-21",
  "publisher": "USPSTF",
  "description": "<p>The USPSTF recommends screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years.<br/>For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with hrHPV testing in combination with cytology (cotesting).<br/><br/>See the <a href=\"https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/cervical-cancer-screening2#consider\">Clinical Considerations section</a> for the relative benefits and harms of alternative screening strategies for women 21 years or older</p>",
  "action": [
    {
      "title": "screening for cervical cancer",
      "textEquivalent": "screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years. For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with hrHPV testing in combination with cytology (cotesting)"
    }
  ]
}